Back to speakers

Michael MANNS

Germany

Contact: manns.michael@mh-hannover.de


Biography of Michael MANNS

Michael P. Manns is Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), Hannover,
Germany since 1991. Since 2015 he is also Clinical Director of the Helmholtz Centre for Infection Research (HZI), Braunschweig, and Founding Director of the Centre for Individualised Infection Medicine (CIIM), Hannover.

He graduated in medicine from the University of Vienna in Austria and the University of Mainz in Germany before completing postgraduate training at the Free University of Berlin, Germany, and the University of Mainz, where he became Professor of Medicine in 1986. Subsequently, Professor Manns was a Research Associate at the Scripps Research Institute in La Jolla, California, USA, from 1987 to 1988.

Professor Manns is founder and Chairman of Hep-Net, a national network of competence on viral hepatitis, and the German Liver Foundation. He has been President of the German Society of Gastroenterology (DGVS), the German Association for the Study of the Liver (GASL), the German Society of Internal Medicine (DGIM) and United European Gastro­enterology (UEG).

Since 2015 Prof. Manns is member of the Scientific Panel for Health (SPH) of the European Commission. Professor Manns has received numerous awards including the International Hans Popper Award in 1995 and the European Association for the Study of the Liver (EASL) Recognition Award in 2007.

Professor Manns has a long-term research interest in liver diseases with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular
carcinoma, liver transplantation and regenerative medicine.

He has published more than 1000 articles in international peer-reviewed journals such as the New England Journal of Medicine, The Lancet, Nature,
Nature Medicine, Cell, Gastroenterology, and Hepatology among others. He has an h-index of 153 (as of May 8, 2018). According to Thomson Reuters he ranks among the top 1 % of most cited researchers in clinical medicine.

PHC's participations

10th PHC – 2017

Tuesday, January 31st 2017

HEPATITIS B - SESSION 2 (chairman)

How to improve access to therapy for HBV patients?

LUNCH WORKSHOPS - 12-Management of autoimmune hepatitis (chairman)

9th PHC – 2016

Monday, January 11th 2016

How to improve access to therapy? Around the World table - NORTH & WEST -

Lunch Workshops - Room 252B (chairman)

New therapeutic strategies (chairman)

8th PHC – 2015

Monday, January 12th 2015

(chairman) -

New therapeutic strategies (chairman)

7th PHC – 2014

Monday, January 13th 2014

How to optimize current therapy of non G1 patients (chairman)

6th PHC – 2013

Monday, January 14th 2013

Optimal treatment with boceprevir -

5th PHC – 2012

Monday, January 30th 2012

Triple therapy today. Phase III results in G1 naïve patients (chairman)

Boceprevir -

Interactive luncheons - Room 5 (chairman)

4th PHC – 2011

Monday, January 17th 2011

New combinations (chairman)

3rd PHC – 2009

Tuesday, January 20th 2009

(chairman)

2nd PHC – 2007

Tuesday, January 23rd 2007

HBeAg positive chronic hepatitis B (chairman)

1st PHC – 2004

Friday, September 10th 2004

Treatment of Acute Hepatitis C (chairman)

10th PHC – 2017

Tuesday, January 31st 2017

HEPATITIS B - SESSION 2 (chairman)

How to improve access to therapy for HBV patients? -

LUNCH WORKSHOPS - 12-Management of autoimmune hepatitis (chairman)

11th PHC – 2018

Monday, January 15th 2018

HEPATITIS C - SESSION 1 (chairman)

Luncheon workshops - (chairman)

12th PHC – 2019

Monday, January 14th 2019

Autoimmune hepatitis